Please ensure Javascript is enabled for purposes of website accessibility

Another Big Failure for VIVUS, Inc.

By Dave Williamson – Feb 25, 2014 at 5:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An awful day for Vivus

Vivus Pharmaceuticals (VVUS) is having an absolutely awful day, with the stock down more than 13% after the company reported its Q4 results. The launch of its first-in-class obesity drug Qsymia was very highly anticipated among investors with the market potential being huge in this space, but sales just aren't panning out that way. The other major competitor in this space is a drug called Belviq from Arena Pharmaceuticals (ARNA), which was also highly anticipated and also disappointed in sales, though sales are better than Qsymia, despite being prescribed roughly half as frequently.

In this video, Motley Fool health-care analyst David Williamson points to Vivus' marketing tactics as one big problem for its sales. The company is offering Qsymia at a discount, with free initial doses followed by doses at $75 per month for up to 3 months. The percentage of free scripts were 23% total. David also looks at why management's suggestion that the poor sales are a seasonal problem doesn't make sense, and looks ahead to one other potential candidate that may finally win the war in the obesity space.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

VIVUS Stock Quote
VIVUS
VVUS
Arena Pharmaceuticals Stock Quote
Arena Pharmaceuticals
ARNA

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.